{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018431","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.367545+00:00","generated_at":"2026-06-05T19:50:44.797359+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio's acoramidis NDA accepted by FDA with PDUFA Nov 29, 2024; secured $1.25B capital; Q4 net loss $168M","bullets":["Acoramidis NDA accepted by FDA; PDUFA Nov 29, 2024. Phase 3 met primary endpoint (Win Ratio 1.8, p<0.0001).","Secured up to $1.25B from Blue Owl and CPP Investments: $500M upfront for 5% royalty on acoramidis net sales and $450M credit facility.","Q4 2023 net loss attributable to common stockholders $168.1M ($0.96 EPS) vs $137.6M ($0.92 EPS) YoY; revenue $1.7M down from $1.9M.","Cash and cash equivalents $392.6M as of Dec 31, 2023. Full year net loss $643.2M; operating cash used $527.7M.","Partnership with Kyowa Kirin for infigratinib in Japan: $100M upfront, royalties up to high-twenties percent, milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018431","json":"https://secwatch.observer/filing/0000950170-24-018431.json","markdown":"https://secwatch.observer/filing/0000950170-24-018431.md","text":"https://secwatch.observer/filing/0000950170-24-018431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/0000950170-24-018431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/bbio-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:50:44.797359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4df5ddd9d3ff34076efecc885723a9b6ba176aa6","claim":"BridgeBio Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"BridgeBio Pharma, Inc. reported recent business updates and its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/0000950170-24-018431-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}